1月29日，瑞可达跌7.47%，成交额9.56亿元。两融数据显示，当日瑞可达获融资买入额1.63亿元，融资 偿还1.50亿元，融资净买入1262.87万元。截至1月29日，瑞可达融资融券余额合计9.95亿元。 融资方面，瑞可达当日融资买入1.63亿元。当前融资余额9.92亿元，占流通市值的5.48%，融资余额超 过近一年80%分位水平，处于高位。 责任编辑：小浪快报 截至9月30日，瑞可达股东户数1.73万，较上期增加7.20%；人均流通股11859股，较上期减少6.72%。 2025年1月-9月，瑞可达实现营业收入23.21亿元，同比增长46.04%；归母净利润2.33亿元，同比增长 119.89%。 分红方面，瑞可达A股上市后累计派现1.64亿元。近三年，累计派现1.30亿元。 机构持仓方面，截止2025年9月30日，瑞可达十大流通股东中，香港中央结算有限公司位居第四大流通 股东，持股702.21万股，相比上期增加544.55万股。海富通股票混合（519005）、华商优势行业混合A （000390）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何 ...

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

Core Viewpoint - The company Ruikeda (688800) has announced its earnings forecast for 2025, projecting a net profit attributable to shareholders of between 288 million to 318 million yuan, representing a year-on-year growth of 64.2% to 81.43% [4]. Financial Performance - The expected net profit for 2025 is between 288 million to 318 million yuan, with a non-recurring net profit forecasted to be between 274 million to 303 million yuan, indicating a year-on-year increase of 67.85% to 85.54% [4]. - As of January 29, the company's price-to-earnings ratio (TTM) is approximately 56.92 to 62.89 times, with a price-to-book ratio (LF) of about 7.89 times and a price-to-sales ratio (TTM) of around 5.75 times [4]. Business Growth Factors - The company's performance improvement is attributed to steady growth across various business segments, leading to an increase in order volume [13]. - Continuous advancements in technology, process innovation, and production automation have enhanced product competitiveness and reduced costs [13]. - Management reforms have begun to yield results, with increased labor efficiency and optimized operational efficiency metrics [13]. - There has been a notable increase in orders from overseas factories compared to the previous year, along with improved operational capabilities [13]. - Initial success has been observed in the expansion of new business areas [13].

瑞可达(688800.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润为2.88亿元到3.18 亿元，与上年同期(法定披露数据)相比，将增加11,253.05万元到14,273.05万元，同比增加64.20%到 81.43%。 ...

证券之星消息，1月29日其他电子板块较上一交易日下跌2.93%，瑞可达领跌。当日上证指数报收于 4157.98，上涨0.16%。深证成指报收于14300.08，下跌0.3%。其他电子板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300656 | 民德电子 | 30.00 | 8.54% | 22.90万 | | 6.83亿 | | 300991 | 创益通 | 41.74 | 7.19% | 11.16万 | | 4.90 Z | | 002782 | 可立克 | 24.24 | 3.90% | 31.34万 | | 7.59亿 | | 300650 | 太龙股份 | 20.15 | 3.28% | 32.15万 | | 6.42亿 | | 301275 | 汉朔科技 | 60.90 | 0.83% | 4.59万 | | 2.84亿 | | 001287 | 中电港 | 26.30 | -0.53% | 41.85万 | | 11.15亿 | | 002 ...

智通财经APP讯，瑞可达(688800.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利 润为2.88亿元到3.18亿元，与上年同期(法定披露数据)相比，将增加11,253.05万元到14,273.05万元，同 比增加64.20%到81.43%。 ...

2025年年度归属上市公司股东的净利润和扣除非经常性损益后的净利润较上年同期有较大幅度的增长， 主要原因是：（1）公司各项业务稳步增长，带动公司订单量持续增加；（2）公司不断推进技术创新、 工艺创新和生产自动化，提升产品竞争力和降低成本；（3）公司管理变革初见成效，单位人效持续增 长，企业运营效率指标持续优化；（4）公司海外工厂订单较上年同期有所增加，工厂运营能力持续提 升；（5）公司新领域业务拓展初见成效。 格隆汇1月29日丨瑞可达(688800.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司所 有者的净利润为28,780.00万元到31,800.00万元，同比增加64.20%到81.43%。归属于母公司所有者的扣 除非经常性损益的净利润为27,420.00万元到30,310.00万元，同比增加67.85%到85.54%。 ...

证券代码：688800 证券简称：瑞可达 $$\underline{{{-\exists\exists}}}\underline{{{-\forall}}}\triangleleft\underline{{{-\neg}}}\triangleleft$$ 苏州瑞可达连接系统股份有限公司 2026 年第一次临时股东会会议资料 苏州瑞可达连接系统股份有限公司 2026 年第一次临时股东会会议资料 | 2026 | 年第一次临时股东会会议须知 2 | | --- | --- | | 2026 | 年第一次临时股东会会议议程 4 | | 2026 | 年第一次临时股东会会议议案 6 | | | 议案一：《关于 年度向金融机构申请综合授信额度及对子公司提供担保额度预计 2026 | | 的议案》 | 7 | | | 议案二：《关于 2026 年度日常关联交易预计的议案》 8 | | | 议案三：《关于增加经营地址并修订<公司章程>的议案》 10 | 苏州瑞可达连接系统股份有限公司 2026 年第一次临时股东会会议资料 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 ...

每经AI快讯，1月29日，瑞可达(688800.SH)公告称，瑞可达预计2025年归属于上市公司股东的净利润为 2.88亿元~3.18亿元，同比增加64.20%~81.43%。主要因业务稳步增长带动订单增加；持续推进技术创 新、工艺创新及生产自动化，提升产品竞争力并降低成本；管理变革初见成效，人效与运营效率提升； 海外工厂订单增长、运营能力增强；新领域业务拓展初见成效。 （文章来源：每日经济新闻） ...

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 287.80 million and 318 million CNY, an increase of 112.53 million to 142.73 million CNY compared to the previous year, representing a year-on-year growth of 64.20% to 81.43%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 274.20 million and 303.10 million CNY, an increase of 110.84 million to 139.74 million CNY compared to the previous year, reflecting a year-on-year increase of 67.85% to 85.54%[5] - The total profit for the previous year was 199.51 million CNY, with a net profit attributable to shareholders of 175.27 million CNY[7] - The company achieved a basic earnings per share of 1.11 CNY in the previous year[8] Growth Drivers - Key drivers for the significant profit growth include steady business growth, increased order volume, ongoing technological and process innovations, and improved operational efficiency[9] - The company has seen an increase in orders from overseas factories compared to the previous year, indicating enhanced operational capacity[9] - The company is making progress in expanding into new business areas, which is beginning to yield results[9] Forecast Validity - The profit forecast has not yet been audited by a registered accountant, and the company has not identified any major uncertainties affecting the accuracy of the forecast[10] - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the official 2025 annual report[11] - The announcement was made by the board of directors of Suzhou Ruikeda Connection System Co., Ltd. on January 30, 2026[12]